Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Kipres Generics Earn Bronchial Asthma Indication in Droves
November 10, 2016
- MSD to Seek Keytruda Listing after Adding Lung Cancer Indication
November 10, 2016
- Takeda to Collaborate with 2 Universities on Application of Miniature Liver Technology to Drug Discovery Research
November 10, 2016
- Kipres AG’s Market Penetration Faster than Expected: Kyorin President
November 9, 2016
- Teva Takeda Pharma “Not a Threat” at Present: Nichi-Iko Pres. Tamura
November 9, 2016
- BIKEN, Mitsubishi Tanabe to Form Vaccine JV Next May
November 8, 2016
- Current Drug Pricing System Became Unfit for New Drugs Like Opdivo: Ono Chief
November 8, 2016
- Ono's Revenue and Profits Soar as Opdivo Sales Jump 1,714%
November 8, 2016
- MSD’s New Dual Oral Hep C Therapy to Challenge Harvoni; Effective Regardless of Resistance Mutations, Renal Impairment
November 8, 2016
- Japan Diabetes Market Likely to Grow 40% by 2024: Fuji Keizai
November 7, 2016
- Eisai’s Halaven Clinches NICE OK as 3rd-Line Breast Cancer Therapy
November 7, 2016
- Mitsubishi Tanabe to Offer Compound Library to Univ. of Tokyo
November 7, 2016
- Acne Med Epiduo Gel Hits Japan Shelves: Maruho
November 7, 2016
- JCR to Provide Temcell for IIT in Epidermolysis Bullosa
November 4, 2016
- Santen Profits Tumble Over 70% on Strong Yen, Divestment; Ophthalmology Biz Brisk
November 4, 2016
- Pfizer Japan Calls Off Transfer of Innovative Drugs after Global Split Plan Scrapped
November 4, 2016
- Mitsubishi Tanabe Licenses Cell Therapy Agent for Knee Osteoarthritis from S. Korean Firm
November 4, 2016
- Mitsubishi Tanabe Ekes Out Sales Rise on Simponi, Other Major Products
November 2, 2016
- Harvoni Top-Seller Drug in Japan in July-September: QuintilesIMS
November 2, 2016
- Strong Yen Dampens Sales of 4 Japanese Majors, but Global Brands Keep Up Momentum
November 2, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…